Nonacog Alfa
Hemophilia A
Baxalta now part of Shireprotein_peptideUnknownDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 73/ 100
Competitive context
62 Active assets in the Hemophilia A cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Turoctocog Alfa Novo Nordisk A/S | Phase 4 | A |
eptacog alfa (activated) AryoGen Pharmed Co. | Phase 4 | A |
Rurioctocog Alfa Pegol Takeda | Phase 4 | BBB |
bay94-9027 Bayer | Phase 4 | BBB |
N8-GP Novo Nordisk A/S | Phase 3 | BBB |
View all 44 →
Same molecule, other indications
Nonacog Alfa is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →